ClinicalTrials.gg
CompletedNCT03318731Updated Sep 25, 2019

Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males

An interventional study of Sugar Pill and Fenugreek Extract, Low Dose in Muscle Damage and Inflammation, sponsored by University of Mary Hardin-Baylor. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by University of Mary Hardin-Baylor · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a randomized, repeated measures and double blind study which measures the effect of fenugreek extract on markers of muscle damage and inflammation in non-resistance trained males. Participants will complete baseline testing and then be randomized into groups. Participants will complete a 2 week, split-body resistance training program. They will then return for testing in which they will complete an overreaching protocol for 5 consecutive days. Measurements will be recorded 24 hrs after the fifth day. Participants will resume the training program for one additional week and return for final measurements.

Read the detailed description

Subjects expressing interest in doing the study will be interviewed in the UMHB Human Performance Lab (HPL) to determine whether they qualify to participate in the study. Upon qualification, participants will be scheduled a familiarization session in which they will be taught how to perform a proper bench press, back squat, deadlift and squat thruster. They will then schedule their first testing session which will include: a body composition analysis via an InBody 770, thigh circumference measurements, joint mobility measurements, a blood draw, strength testing (1RM), and muscular endurance testing (70% 1RM max reps). Participants will then be placed in groups based on fat free mass and assigned their workout program (3days/week) with training loads based on their 1RM values (bench press, back squat, deadlift and squat thruster).

Supplementation protocol: Participants will be randomly assigned into one of three groups and instructed to ingest capsules of either a placebo, or IND03 (fenugreek extract) containing 300mg, or 500mg. They will supplement 1 hour prior to their workout each exercise day as well as during the overreaching week. On "off/rest" days, participants will consume capsules in the morning with breakfast.

After two weeks of training, participants will return to the HPL for follow-up strength testing (1RM), and muscular endurance testing (70% 1RM max reps), then instructed to rest for 48 hours and return to the lab to begin their overreaching protocol. During each of the 5 days, participants undergo the following measurements prior to the exercise protocol: thigh circumference, joint mobility, and questionnaires (WOMAC \& VAS). On Day 1 participants will also perform an InBody and blood draw. A blood draw will also be performed on Day 3. They will then consume a standardized snack and begin the overreaching protocol of 8 sets of 10 repetitions for the following 4 exercises: bench press, back squat, deadlift and squat thruster. There will be a 1 minute rest period in between each set and a 2 minute rest in between each exercise. Participants will then fill out a Rate of Perceived Exertion (RPE) immediately after the protocol. Again, they will perform this for 5 consecutive days.

Twenty-four hours after the last overreaching day, participants will return for thigh circumference, joint mobility, questionnaires (WOMAC \& VAS), a blood draw, strength testing (1RM), and muscular endurance testing (70% 1RM max reps). They will then be instructed to continue the resistance training program for 1 week. After that period they will return for final measurements of thigh circumference, joint mobility, questionnaires (WOMAC \& VAS), a blood draw, strength testing (1RM), and muscular endurance testing (70% 1RM max reps).

Throughout the duration of the study, participants will record their dietary intake via MyFitnessPal.

02

Conditions studied

  • Muscle Damage
  • Inflammation

Browse trials for

Keywords

  • fenugreek extract
  • non-resistance trained
03

In context

Inflammation

3,536 studies on the registry are indexed under Inflammation; 642 are open to participants now.

This study's enrollment of 60 is above the median of 50 across 2,577 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

University of Mary Hardin-Baylor is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be males between the age of 18-45;
  • Subjects will have not been participating in a structured resistance training program in the past 6 months;
  • Subjects will be provided written and dated to participate in the study;
  • Subjects will be willing and able to comply with the protocol;
  • Subjects will be apparently healthy and free from disease, as determined by a health history questionnaire;
  • Subjects will agree to abstain from exercise 48 hours prior to each testing visit;
  • Subjects will agree to fast for 10 hours prior to each testing visit;
  • Subjects will be agree to refrain from tobacco use, alcohol and/or caffeine consumption and/or smoking 12 hours prior to each testing visit;
  • Subjects will agree to refrain from taking any supplement that may interfere with study supplementation for the remainder of the study.

Exclusion criteria

Exclusion Criteria:

  • Subject has taken ergogenic levels of nutritional supplements that may affect muscle mass (e.g., creatine, HMB) or anabolic/catabolic hormone levels (e.g., androstenedione, DHEA, etc.) within 3 months prior to the start of the study;
  • Subject is unable to complete blood draws needed at each testing session;
  • Subject reports any unusual adverse events associated with this study that in consultation with the supervising physician recommends removal from the study;
  • Subject does not complete 90% of resistance training program assigned;
  • Subject is unable to complete overreaching protocol during overreaching week;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Placebo comparator
    Sugar Pill

    Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.

    Other: Sugar Pill

  • Experimental
    Fenugreek Extract, Low Dose

    300mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.

    Dietary Supplement: Fenugreek Extract, Low Dose

  • Experimental
    Fenugreek Extract, High Dose

    500mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.

    Dietary Supplement: Fenugreek Extract, High Dose

Interventions

  • OtherSugar Pill

    Taken orally in capsule form

  • Dietary supplementFenugreek Extract, Low Dose

    Taken orally in capsule form

  • Dietary supplementFenugreek Extract, High Dose

    Taken orally in capsule form

06

What researchers measure

Primary outcomes

  1. Effect of Fenugreek Extract on Interleukin-1

    The primary purpose of this investigation is to determine the effectiveness of fenugreek extract on blunting an exercise-induced state of inflammation during a period of high volume and overreaching resistance exercise in young, non-resistance trained males. This will be accomplished by observing blood markers prior to, during and post exercise testing.

    Time frame: within 26 days

  2. Effect of Fenugreek Extract on Creatine Kinase

    The primary purpose of this investigation is to determine if supplementation of fenugreek extract will have a protective effect on muscle damage in response to resistance exercise. This will be accomplished by observing blood markers prior to, during and post exercise testing.

    Time frame: within 26 days

  3. Effect of Fenugreek Extract on Interleukin-6

    The primary purpose of this investigation is to determine the effectiveness of fenugreek extract on blunting an exercise-induced state of inflammation during a period of high volume and overreaching resistance exercise in young, non-resistance trained males. This will be accomplished by observing blood markers prior to, during and post exercise testing.

    Time frame: within 26 days

  4. Effect of Fenugreek Extract on Tumor Necrosis Factor Alpha (TNF-α)

    The primary purpose of this investigation is to determine the effectiveness of fenugreek extract on blunting an exercise-induced state of inflammation during a period of high volume and overreaching resistance exercise in young, non-resistance trained males. This will be accomplished by observing blood markers prior to, during and post exercise testing.

    Time frame: within 26 days

  5. Effect of Fenugreek Extract on C-reactive protein

    The primary purpose of this investigation is to determine the effectiveness of fenugreek extract on blunting an exercise-induced state of inflammation during a period of high volume and overreaching resistance exercise in young, non-resistance trained males. This will be accomplished by observing blood markers prior to, during and post exercise testing.

    Time frame: within 26 days

  6. Effect of Fenugreek Extract on 3-methylhistidine

    The primary purpose of this investigation is to determine if supplementation of fenugreek extract will have a protective effect on muscle damage in response to resistance exercise. This will be accomplished by observing blood markers prior to, during and post exercise testing.

    Time frame: within 26 days

  7. Effect of Fenugreek Extract on Lactate Dehydrogenase

    The primary purpose of this investigation is to determine if supplementation of fenugreek extract will have a protective effect on muscle damage in response to resistance exercise. This will be accomplished by observing blood markers prior to, during and post exercise testing.

    Time frame: within 26 days

Secondary outcomes

  1. Effect of Fenugreek Extract on Glucose mg/dL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  2. Effect of Fenugreek Extract on Urea Nitrogen (BUN) mg/Dl

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  3. Effect of Fenugreek Extract on Creatinine mg/Dl

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  4. Effect of Fenugreek Extract on eGFR Non-Afr. American mL/min/1.73m2

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  5. Effect of Fenugreek Extract on eGFR African American mL/min/1.73m2

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  6. Effect of Fenugreek Extract on BUN/Creatinine Ratio calculated

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  7. Effect of Fenugreek Extract on Sodium mmol/L

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  8. Effect of Fenugreek Extract on Potassium mmol/L

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  9. Effect of Fenugreek Extract on Chloride mmol/L

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  10. Effect of Fenugreek Extract on Carbon Dioxide mmol/L

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  11. Effect of Fenugreek Extract on Calcium mg/Dl

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  12. Effect of Fenugreek Extract on Protein, Total g/Dl

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  13. Effect of Fenugreek Extract on Albumin g/dL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  14. Effect of Fenugreek Extract on Globulin g/Dl

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  15. Effect of Fenugreek Extract on Albumin/Globulin Ratio calculated

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  16. Effect of Fenugreek Extract on Bilirubin, Total mg/Dl

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  17. Effect of Fenugreek Extract on Alkaline Phosphatase U/L

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  18. Effect of Fenugreek Extract on Aspartate Aminotransferase U/L

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  19. Effect of Fenugreek Extract on Alanine Aminotransferase U/L

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.

    Time frame: within 26 days

  20. Effect of Fenugreek Extract on White Blood Cell Count thousand/uL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  21. Effect of Fenugreek Extract on Red Blood Cell Count million/uL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  22. Effect of Fenugreek Extract on Hemoglobin g/dL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  23. Effect of Fenugreek Extract on Hematocrit %

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  24. Effect of Fenugreek Extract on MCV fL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  25. Effect of Fenugreek Extract on MCH pg

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  26. Effect of Fenugreek Extract on MCHC g/dL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  27. Effect of Fenugreek Extract on RDW %

    v

    Time frame: within 26 days

  28. Effect of Fenugreek Extract on Platelet Count thousand/uL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  29. Effect of Fenugreek Extract on MPV fL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  30. Effect of Fenugreek Extract on Absolute Neutrophils cells/uL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  31. Effect of Fenugreek Extract on Absolute Lymphocytes cells/uL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  32. Effect of Fenugreek Extract on Absolute Monocytes cells/uL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  33. Effect of Fenugreek Extract on Absolute Eosinophils cells/uL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  34. Effect of Fenugreek Extract on Absolute Basophils cells/uL

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  35. Effect of Fenugreek Extract on Neutrophils %

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  36. Effect of Fenugreek Extract on Lymphocytes %

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  37. Effect of Fenugreek Extract on Monocytes %

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  38. Effect of Fenugreek Extract on Eosinophils %

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

  39. Effect of Fenugreek Extract on Basophils %

    The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.

    Time frame: within 26 days

07

Study locations

1 site
  • UMHB Human Performance Lab
    Belton, Texas 76513, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in May 2019, 20 months.

Of 877 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 20 months is above that.

Counting every sponsor, half of 924 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 24, 2017
StartActual
Sep 21, 2017
Primary completionActual
May 24, 2019
CompletionActual
Aug 30, 2019
Last update
Sep 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03318731
Lead sponsor
University of Mary Hardin-Baylor
Collaborators
Indus Biotech Ltd. Pvt.
Responsible party
Sponsor
First posted
Oct 24, 2017
Start date
Sep 21, 2017
Primary completion
May 24, 2019
Completion
Aug 30, 2019
Last update
Sep 25, 2019

Study contacts

Lemuel W Taylor IV, PhD
principal investigator · UMHB Human Performance Lab

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion